HARMONY ALERT: Bragar Eagel & Squire, P.C. is Investigating Harmony Biosciences Holdings, Inc. on Behalf of Harmony Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY) on behalf of Harmony stockholders. Our investigation concerns whether Harmony has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On March 28, 2023, Scorpion Capital ("Scorpion") published a short report on Harmony, which Scorpion described as "[o]ne of the most thoroughly corrupt healthcare schemes in recent years, deserving of criminal and political scrutiny". Scorpion described "Harmony's drug Wakix (pitolisant) [as] a repeat of the Seldane (terfenadine) saga, another histamine antagonist that the FDA pulled from the market and which is the poster child for cardiac toxicity via fatal QT prolongation/arrhythmia." Scorpion asserted that it "obtained dozens of serious adverse event reports from the FDA via Freedom of Information Act requests filed over several months, and they paint a devastating picture of the drug's risk to even young, otherwise healthy patients, including a recent sudden cardiac death, 2 weeks after starting Wakix on the day it was titrated to the highest dose."

On this news, Harmony's stock price fell sharply during intraday trading on March 28, 2023.

If you purchased or otherwise acquired Harmony shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [e-mail], by telephone at [phone], or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.